SOPHiA GENETICS SA (SOPH)
NASDAQ: SOPH · Real-Time Price · USD
3.295
+0.035 (1.07%)
Mar 31, 2025, 2:24 PM EDT - Market open
Company Description
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space.
The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
SOPHiA GENETICS SA
Country | Switzerland |
Founded | 2011 |
IPO Date | Jul 23, 2021 |
Industry | Health Information Services |
Sector | Healthcare |
Employees | 423 |
CEO | Jurgi Camblong |
Contact Details
Address: La PiEce 12 Rolle, 1180 Switzerland | |
Phone | 41 21 694 10 60 |
Website | sophiagenetics.com |
Stock Details
Ticker Symbol | SOPH |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001840706 |
CUSIP Number | H82027105 |
ISIN Number | CH1125843347 |
SIC Code | 7374 |
Key Executives
Name | Position |
---|---|
Dr. Jurgi Camblong M.B.A., Ph.D. | Co-Founder, Chief Executive Officer and Director |
Ross Jordan Muken B.Sc. | President |
George A. Cardoza M.B.A. | Executive Vice President and Chief Financial Officer |
Abhimanyu Verma | Senior Vice President and Chief Technology Officer |
Dr. Zhenyu Xu Ph.D. | Executive Vice President and Chief Scientific Officer |
Kellen Sanger | Head of Strategy and Investor Relations |
Daan van Well L.L.M., M.B.A. | Executive Vice President, Chief Legal and Regulatory Officer |
Manuela Da Silva Valente B.A. | Executive Vice President and Chief People Officer |
Kevin Puylaert | Vice President and MD of EMEA |
Dr. Philippe Menu M.B.A., M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Chief Product Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 24, 2025 | 144 | Filing |
Mar 24, 2025 | 144 | Filing |
Mar 24, 2025 | 144 | Filing |
Mar 19, 2025 | 144 | Filing |
Mar 4, 2025 | 20-F | Annual and transition report of foreign private issuers |
Mar 4, 2025 | 6-K | Report of foreign issuer |
Feb 19, 2025 | 144 | Filing |
Feb 19, 2025 | 144 | Filing |
Jan 27, 2025 | 144 | Filing |
Jan 27, 2025 | 144 | Filing |